



**5th Annual Hereditary Cancer Symposium for Health Care Providers**  
**Internet Live Activity**  
**Activity ID: 16325**  
**April 1-2, 2022**

**Learning Objectives:**

1. Implement guidelines to assess and screen high-risk patients in daily practice
2. Identify and document key features associated with potential hereditary cancer predisposition adequately to refer at risk patients for cancer assessment
3. Articulate and implement surgical interventions, screening protocols, and system therapies appropriate for specific hereditary cancer predisposition syndrome/genes
4. Describe impact of genetic testing results on the patient psychosocially and medically for current and long-term management
5. Identify a genetic counseling service delivery model that fits their clinical practice and implement a referral strategy
6. Differentiate the utility of various genetic testing modalities commonly used related to oncology risk and care

**Nursing Learning Outcomes:**

1. Describe the impact of genetic testing results on the patient psychosocially and medically for current and long-term management
2. Identify a genetic counseling service delivery model that fits their clinical practice and implement a referral strategy
3. Differentiate the utility of various genetic testing modalities commonly used related to oncology risk and care

**Accreditation/Credit Designation - Physician**

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 9.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Ethics:**

The session, *Ethical Considerations for GT*, has been designated by The University of Texas MD Anderson Cancer Center for 0.50 *AMA PRA Category 1 Credit™* in medical ethics and/or professional responsibility.

**Accreditation/Credit Designation - Nursing**

The University of Texas MD Anderson Cancer Center is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Texas MD Anderson Cancer Center designates this live activity will award 9.75 Nursing Continuing Professional Development (NCPD) contact hours.

**Commercial Support:**

The symposium organizing committee wishes to express appreciation to the following companies for their commitment to continuing medical education by providing an educational grant in support of this activity: AstraZeneca Pharmaceuticals, Merck Sharp & Dohme Corp and Pfizer Inc. (*confirmed as of March 29, 2022*).

**Disclosure:**

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Lori A Dangler, MD, MBA, FASA	CE Reviewer	Nothing to disclose
Y Nancy You, MD, MHSc	Co-Director	Nothing to disclose
Banu K Arun, MD, FASCO	Co-Director, Faculty	Grant or research support-AstraZeneca US
Autumn Vara, MS, CGC	Co-Director, Faculty	Nothing to disclose
Jessica Corredor, MS, CGC, Certified Genetic Counselor	Faculty	Nothing to disclose
Molly Daniels, MS, CGC	Faculty	Nothing to disclose
Sandra Darilek, MS, CGC	Faculty	Nothing to disclose
Courtney D DiNardo, MD	Faculty	Honoraria-AbbVie Inc.   Honoraria-Agios Pharmaceuticals Inc.   Honoraria-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended)   Honoraria-Bristol-Myers Squibb Company   Honoraria-Celgene Corporation   Honoraria-GlaxoSmithKline   Honoraria-Jazz Pharmaceuticals   Honoraria-Novartis Pharmaceuticals Corporation (Relationship has ended)   Honoraria-Servier Pharmaceuticals
Bryan Joyce	Faculty	Nothing to disclose
Rachel M Layman, MD	Faculty	Grant or research support-Lilly USA, LLC   Paid consultant-Lilly USA, LLC   Grant or research support-Novartis Pharmaceuticals Corporation   Paid consultant-Novartis Pharmaceuticals Corporation (Relationship has ended)   Grant or research support-Pfizer Inc.   Grant or research support-GlaxoSmithKline (Relationship has ended)   Grant or research support-Puma   Grant or research support-Zentalis   Grant or research support-Celcuity   Paid consultant-Celcuity (Relationship has ended)
Sharon Mattox, MSN	Faculty	Nothing to disclose

Victoria McClosky, BSN, CBCN	Faculty	Nothing to disclose
Jason Metts , MBA	Faculty	Nothing to disclose
Larissa M Meyer, MD, MPH, FACS, FACOG	Faculty	Grant or research support-AstraZeneca US Stocks or stock options, excluding diversified mutual funds-Johnson & Johnson (any division) Stocks or stock options, excluding diversified mutual funds-Crispr Therapeutics Stocks or stock options, excluding diversified mutual funds-Bristol-Myers Squibb Company Stocks or stock options, excluding diversified mutual funds-Invitae Membership on Advisory Committees or Review Panels, Board Membership, etc.-GlaxoSmithKline (Relationship has ended)
Jessica A. Moore, DHCE, DHCE	Faculty	Nothing to disclose
Maureen Mork, MS	Faculty	Nothing to disclose
Michael J Overman, MD	Faculty	Consulting Fee-roche, BMS, Medimmune, Merck, Amgen, Takeda, Janssen, Pfizer, Array, Gritistone, 3DMed, Phanes
Nadine Rayes, MS, Licensed and Certified Genetic Counselor	Faculty	Nothing to disclose
Donika Saporito, MS	Faculty	Royalties or Patent Beneficiary-UpToDate
Jennifer Scull, PhD, FACMG	Faculty	Nothing to disclose
Marne Shafer	Faculty	Nothing to disclose
Catherine Skefos, MS, CGC	Faculty	Nothing to disclose
Yoheved Gerstein, MS, Certified Genetic Counselor	Faculty, Other Planning Committee Member	Nothing to disclose
Andrew McKeon, MS, CGC	Faculty, Other Planning Committee Member	Nothing to disclose
Patti A Heitz, MEd, RN	Nurse Planner	Nothing to disclose
Hiam Abdel-Salam, MS, CGC	Other Planning Committee Member	Nothing to disclose
Felisha Estelle, BBA	Other Planning Committee Member	Nothing to disclose
Sierra Green, BS	Other Planning Committee Member	Nothing to disclose
Linda T Hill	Other Planning Committee Member	Nothing to disclose
Walter Knowles, MBA	Other Planning Committee Member	Nothing to disclose
Julie Moskowitz, MS, CGC	Other Planning Committee Member	Nothing to disclose
Bradley Power, MS, CGC	Other Planning Committee Member	Nothing to disclose

Susan Reilly, MS, Certified Genetic Counselor	Other Planning Committee Member	Nothing to disclose
Rachael Shilbauer, MGCS, CGC	Other Planning Committee Member	Nothing to disclose
JACYNDA WOODMAN-ROSS, MS, CGC	Other Planning Committee Member	Nothing to disclose

**REQUIREMENTS FOR SUCCESSFUL COMPLETION:**

To claim CE credits for this activity, the participant must:

**1. Professional Education Portal (PEP):**

- Create an account and complete profile in (PEP)
- Profiles need to include the following: Degree, Profession, email address and mobile number
- Pair your email address to PEP (must use email address used to create PEP account). This is a **one-time** only process to allow you to log your attendance using the text messaging feature. Pairing your phone to the system is done by sending a **text** of your **email address** to **1-844-912-1333**.

**2. Register** for and attend all sessions of this activity.

**3. Record Attendance:** During the activity, TEXT the code: **16325** to **1-844-912-1333** (**texting to record attendance only needs to be done once for the duration of the activity**). You will have up to **24 hours** after the activity has ended to text this code in order to have your attendance recorded.

**4. Evaluation:** Complete the participant evaluation in PEP. **Evaluation will expire on Monday, May 2 at 11:00 pm (CT).**